Effect of HIV type 1 subtype on virological and immunological response to combination antiretroviral therapy: Evidence for a more rapid viral suppression for subtype A than subtype B-infected Greek individuals

AIDS Research and Human Retroviruses

Volumn 29, Issue 3, 2013, Pages 461-469

  Paraskevis, Dimirios ^a   Touloumi, Giota ^a   Bakoyannis, Giorgos ^a   Paparizos, Vassilios ^a   Lazanas, Marios ^b   Gargalianos, Panagiotis ^c   Chryssos, Georgios ^d   Antoniadou, Anastasia ^e   Psichogiou, Mina ^f   Panos, Georgios ^g   Katsarou, Olga ^f   Sambatakou, Helen ^a   Kordossis, Theodoros ^f   Hatzakis, Angelos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b KAT HOSPITAL   (Greece)

^c G GENNIMATAS GENERAL HOSPITAL   (Greece)

^d TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^e NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^f UNIVERSITY OF ATHENS   (Greece)

^g Internal Medicine   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ARTICLE; DRUG TREATMENT FAILURE; EUROPE; FEMALE; GREECE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; GENOTYPE; GREECE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84874487228     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0143     Document Type: Article

References (38)

1. Sharp PM and Hahn BH: The evolution of HIV-1 and the origin of AIDS. Phil Transact Royal Soc London, Ser B, Biol Sci 2010;365(1552):2487-2494.
2. Hemelaar J, Gouws E, Ghys PD, and Osmanov S: Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011;25(5):679-689.
3. Perrin L, Kaiser L, and Yerly S: Travel and the spread of HIV-1 genetic variants. Lancet Infect Dis 2003;3(1):22-27.
4. Thomson MM and Najera R: Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: An update. AIDS Rev 2005;7(4):210-224.
5. Buve A, Bishikwabo-Nsarhaza K, and Mutangadura G: The spread and effect of HIV-1 infection in sub-Saharan Africa. Lancet 2002;359(9322):2011-2017.
6. Tebit DM and Arts EJ: Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis 2011;11(1):45-56.
7. Paraskevis D, Pybus O, Magiorkinis G, et al.: Tracing the HIV-1 subtype B mobility in Europe: A phylogeographic approach. Retrovirology 2009;6:49.
8. Grenfell BT, Pybus OG, Gog JR, et al.: Unifying the epidemiological and evolutionary dynamics of pathogens. Science 2004;303(5656):327-332.
9. Pybus OG and Rambaut A: Evolutionary analysis of the dynamics of viral infectious disease. Nature Rev Genet 2009;10(8):540-550.
10. Korber B, Muldoon M, Theiler J, et al.: Timing the ancestor of the HIV-1 pandemic strains. Science 2000;288(5472):1789-1796.
11. Brennan CA, Bodelle P, Coffey R, et al.: HIV global surveillance: Foundation for retroviral discovery and assay development. J Med Virol 2006;78(Suppl 1):S24-29.
12. Hu DJ, Dondero TJ, Rayfield MA, et al.: The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention. JAMA 1996;275(3): 210-216.
13. de Arellano ER, Benito JM, Soriano V, Lopez M, and Holguin A: Impact of ethnicity and HIV type 1 subtype on response to first-line antiretroviral therapy. AIDS Res Hum Retroviruses 2007;23(7):891-894.
14. Holguin A, Ramirez de Arellano E, Rivas P, and Soriano V: Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. AIDS Rev 2006;8(2):98-107.
15. Frater AJ, Dunn DT, Beardall AJ, et al.: Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 2002;16(8):1139-1146.
16. Bannister WP, Ruiz L, Loveday C, et al.: HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antiviral Ther 2006;11(6):707-715.
17. Geretti AM, Harrison L, Green H, et al.: Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 2009; 48(9):1296-1305.
18. Easterbrook PJ, Smith M, Mullen J, et al.: Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Internat AIDS So 2010;13:4.
19. Atlas A, Granath F, Lindstrom A, Lidman K, Lindback S, and Alaeus A: Impact of HIV type 1 genetic subtype on the outcome of antiretroviral therapy. AIDS Res Hum Retroviruses 2005;21(3):221-227.
20. Alexander CS, Montessori V, Wynhoven B, et al.: Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. Antiviral Ther 2002;7(1):31-35.
21. Nicastri E, Sarmati L, d'Ettorre G, et al.: Non-B HIV type 1 subtypes: Replicative capacity and response to antiretroviral therapy. AIDS Res Hum Retroviruses 2004;20(8):816-818.
22. Bocket L, Cheret A, Deuffic-Burban S, et al.: Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antiviral Ther 2005; 10(2):247-254.
23. De Wit S, Boulme R, Poll B, Schmit JC, and Clumeck N: Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients. AIDS 2004;18(17):2330-2331.
24. Paraskevis D, Magiorkinis E, Magiorkinis G, et al.: Increasing prevalence of HIV-1 subtype A in Greece: Estimating epidemic history and origin. J Infect Dis 2007;196(8):1167-1176.
25. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. October 14, 2011, 1-167. Available at http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL. pdf.
26. Thompson JD, Higgins DG, and Gibson TJ: CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22(22):4673-4680.
27. Aalen S: An empirical transition matrix for non-homogeneous Markov chains based on censored observations. Scand J Stat 1978;5:141-150.
28. Kalbfleisch JD, et al.: The Statistical Analysis of Failure Time Data. Wiley, New York, 2002.
29. Abecasis AW, Vercauteren AMJ, Paraskevis J, et al.: Genetic diversity of HIV-1 in Europe and its demographic determinants (2002-2005). Paper presented at the 9th European Workshop on HIV and Hepatitis - Treatment Strategies and Antiviral Drug Resistance, 2011, Paphos, Cyprus.
30. Scherrer AU, Ledergerber B, von Wyl V, et al.: Improved virological outcome in white patients infected with HIV-1 non-B subtypes compared to subtype B. Clin Infect Dis 2011;53(11):1143-1152.
31. Tebit DM, Nankya I, Arts EJ, and Gao Y: HIV diversity, recombination and disease progression: How does fitness "fit" into the puzzle? AIDS Rev 2007;9(2):75-87.
32. Arien KK, Abraha A, Quinones-Mateu ME, Kestens L, Vanham G, and Arts EJ: The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol 2005;79(14):8979-8990.
33. Novitsky V, Wang R, Bussmann H, et al.: HIV-1 subtype Cinfected individuals maintaining high viral load as potential targets for the ''test-And-treat'' approach to reduce HIV transmission. PloS One 2010;5(4):e10148.
34. Laurent C, Bourgeois A, Faye MA, et al.: No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02-AG strain and patients not infected with CRF02-AG, in Western and West-Central Africa: A four-year prospective multicenter study. J Infect Dis 2002;186(4):486-492.
35. Vasan A, Renjifo B, Hertzmark E, et al.: Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006;42(6):843-852.
36. Ng OT, Lin L, Laeyendecker O, et al.: Increased rate of CD4 + T-cell decline and faster time to antiretroviral therapy in HIV-1 subtype CRF01-AE infected seroconverters in Singapore. PloS One 2011;6(1):e15738.
37. Chohan B, Lang D, Sagar M, et al.: Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 2005;79(10):6528-6531.
38. Magiorkinis EP, Zavitsanou D, Beloukas A, et al.: Prevalence, temporal patterns and clusters of transmitted drug resistance in newly diagnosed HIV-1 infected patients in Greece over the last decade. 13th European AIDS Conference, Belgrade, 2011.